Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 265 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: GlucoCorticoid Clear all

Conditions: Osteoporosis
Interventions: Alendronate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Not listed
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, Standard Care; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morehead City, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: PF-04171327, prednisone, prednisone, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 14
States / cities: Tucson, Arizona • San Leandro, California • Newark, Delaware + 9 more

Conditions: Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
Interventions: Osilodrostat; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Betamethasone; Drug
Lead sponsor: Emory University; Other
Eligibility: Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Bronchopulmonary Dysplasia
Interventions: Dexamethasone Early, Dexamethasone Late; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 13 Days to 15 Days
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1994
U.S. locations: 13
States / cities: Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more

Conditions: Myositis, Dermatomyositis, Polymyositis
Interventions: Healthy Control, Myositis in Remission; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: PF-04308515, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Lupus
Interventions: Prasterone (GL701); Drug
Lead sponsor: Genelabs Technologies; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 25
States / cities: Tucson, Arizona • Los Angeles, California • North Hollywood, California + 22 more

Conditions: Postoperative Pain, Inflammation, Osteoarthritis
Interventions: Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo; Drug
Lead sponsor: Thomas L Bradbury; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Hypogonadism
Interventions: Jatenzo Oral Product; Drug
Lead sponsor: Tolmar Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 27
States / cities: Tempe, Arizona • Lincoln, California • Long Beach, California + 23 more

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 62
States / cities: Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more

Conditions: Congenital Adrenal Hyperplasia (CAH)
Interventions: Fludrocortisone, Hydrocortisone, Letrozole, Flutamide, Testolactone; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Alcohol-associated Hepatitis
Interventions: IL-22, Prednisone, Acamprosate, Prednisone placebo, IL-22 (F-652) Placebo, Motivational Interviewing (MI), Motivational Enhancement Therapy (MET), Usual Care; Drug · Behavioral
Lead sponsor: Samer Gawrieh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: Indianapolis, Indiana • Louisville, Kentucky • Rochester, Minnesota + 3 more

Conditions: Glucose Homeostasis, Protein Metabolism, Lipid Metabolism, Respiratory Function, Connective Tissue Metabolism
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 278 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Healthy Adults
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more

Conditions: Osteoporosis
Interventions: Actonel; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Glucocorticoids Toxicity, Glucose Intolerance
Interventions: Prednisone; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Prostate Cancer Metastatic
Interventions: ODM-208, Midazolam; Drug
Lead sponsor: Orion Corporation, Orion Pharma; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 4
States / cities: Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more

Conditions: Anesthesia, Local, Shoulder Surgery
Interventions: saline, Dexamethasone, ropivacaine, Bupivacaine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Takayasu's Arteritis, Giant Cell Arteritis
Interventions: Abatacept, Placebo; Drug
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 15 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 8
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 5 more

Conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions: Ublituximab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions: GlucoCorticoid; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 1 Day to 5 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

Treatment of Childhood Osteoporosis With Alendronate (Fosamax)

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section

Dexamethasone Therapy in VLBW Infants at Risk of CLD

Predictor of Clinical Response to Acthar in Myositis

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids

Steroids in Total Knee Arthroplasty

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease

The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid Therapy

Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids

Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer

The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Glucocorticoids and Pulmonary Hypertension